tulmimetostat (DZR123)

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

EZH2 inhibitor, EZH1 inhibitor

Related drugs:

ARID1A mutation	Endometrial Cancer	ARID1A mutation	Endometrial Cancer	DZR123 Sensitive: B - Late Trials DZR123 Sensitive : B	DZR123 Sensitive: B - Late Trials DZR123 Sensitive : B
ARID1A mutation	Ovarian Cancer	ARID1A mutation	Ovarian Cancer	DZR123 Sensitive: C2 – Inclusion Criteria DZR123 Sensitive : C2	DZR123 Sensitive: C2 – Inclusion Criteria DZR123 Sensitive : C2
AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	DZR123 Sensitive: D – Preclinical DZR123 Sensitive : D	DZR123 Sensitive: D – Preclinical DZR123 Sensitive : D

Associations
(3)